Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 21 Stockholm, Sweden.
Biomolecules. 2012 Dec 14;2(4):635-49. doi: 10.3390/biom2040635.
Treatments with Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors have offered patients carrying cancers with mutated BRCA1 or BRCA2 genes a new and in many cases effective option for disease control. There is potentially a large patient population that may also benefit from PARP inhibitor treatment, either in monotherapy or in combination with chemotherapy. Here, we describe the multifaceted role of PARP inhibitors and discuss which treatment options could potentially be useful to gain disease control without potentiating side effects.
聚（腺苷二磷酸核糖）聚合酶（PARP）抑制剂的治疗为携带突变 BRCA1 或 BRCA2 基因的癌症患者提供了一种新的、在许多情况下有效的疾病控制选择。可能有大量的患者群体也可以从 PARP 抑制剂治疗中受益，无论是单独使用还是与化疗联合使用。在这里，我们描述了 PARP 抑制剂的多方面作用，并讨论了哪些治疗选择可能有助于在不增加副作用的情况下获得疾病控制。
